Literature DB >> 15774410

Cocaine-related torsade de pointes in a methadone maintenance patient.

Mori J Krantz1, Shane B Rowan, Philip S Mehler.   

Abstract

A patient maintained on methadone for opioid-dependency developed recurrent syncope. Episodes occurred within hours after using cocaine, and were initially presumed secondary to seizure disorder. However, the patient subsequently suffered a cardiac arrest, and polymorphic ventricular tachycardia (torsade de pointes) was documented. Other than cocaine and methadone the patient was receiving no additional agents known to prolong the QT interval. Low serum methadone concentrations and marked reversible left ventricular systolic dysfunction were noted during the hospitalization. These findings, in conjunction with a history of torsade de pointes temporally related to cocaine abuse, suggest that cocaine was a major precipitant of arrhythmia. Recent experimental studies have shown that cocaine and methadone prolong the QT interval through the same mechanism. We examine the effects of cocaine and methadone on cardiac conduction in the context of the opioid-dependent population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774410     DOI: 10.1300/J069v24n01_05

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  10 in total

Review 1.  Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside.

Authors:  Robert S Hoffman
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

Review 2.  Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias.

Authors:  Michael E O'Leary; Jules C Hancox
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

3.  Torsades de pointes associated with methadone and voriconazole.

Authors:  Jennifer A Reinhold; Cynthia A Sanoski; Andrea M Russo; Joshua M Cooper; Sarah A Spinler
Journal:  BMJ Case Rep       Date:  2009-12-22

4.  A twist on torsade: a prolonged QT interval on methadone.

Authors:  Patricia Lamont; Susan C Hunt
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

Review 5.  Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article.

Authors:  Farshid Etaee; Morgan Tobin; Suchith Vuppala; Alireza Komaki; Brian P Delisle; Luigi Di Biase; John N Catanzaro; Andrea Natale; Claude S Elayi
Journal:  J Interv Card Electrophysiol       Date:  2021-10-21       Impact factor: 1.900

6.  Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data.

Authors:  David Kao; Becki Bucher Bartelson; Vaishali Khatri; Richard Dart; Philip S Mehler; David Katz; Mori J Krantz
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

7.  Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem.

Authors:  W Victor R Vieweg; Mehrul Hasnain; Robert H Howland; Thomas Clausen; Jayanthi N Koneru; Christopher Kogut; Ericka L Breden Crouse; Jules C Hancox; Antony Fernandez; Ananda K Pandurangi
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

8.  S100B protein expression in the heart of deceased individuals by overdose: a new forensic marker?

Authors:  Armando Faa; Giancarlo Senes; Annalisa Locci; Pietro Pampaloni; Maria Elena Pais; Bruno Piras; Ernesto d'Aloja; Gavino Faa
Journal:  Clinics (Sao Paulo)       Date:  2012-07       Impact factor: 2.365

Review 9.  A systematic review of the cardiotoxicity of methadone.

Authors:  Samira Alinejad; Toba Kazemi; Nasim Zamani; Robert S Hoffman; Omid Mehrpour
Journal:  EXCLI J       Date:  2015-05-05       Impact factor: 4.068

Review 10.  Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.

Authors:  Florian Lemaitre; Caroline Solas; Matthieu Grégoire; Laurence Lagarce; Laure Elens; Elisabeth Polard; Béatrice Saint-Salvi; Agnès Sommet; Michel Tod; Chantal Barin-Le Guellec
Journal:  Fundam Clin Pharmacol       Date:  2020-07-24       Impact factor: 2.747

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.